Spectral Medical Inc. announced that it has enrolled a total of 69 patients for the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Rutgers, The State University of New Jersey (RU) enrolled its first patient within three weeks of opening for enrollment in the Tigris Trial. University of Alabama at Birmingham (UAB) enrolled its second patient in less than a month since opening forrollment in the Tigris Trial.

69 patients enrolled to date and continuing to close in on the interim target of 90 patients, an important milestone as the Company's strategic commercial partner, Baxter, will have the opportunity to view the data as well as provide a second milestone payment to Spectral. Based on the enrollment rate experienced over the past three months, the Company remains on pace to achieve its target timeline of 90 patients enrolled around the end of 2023. On track to achieve 25 active trial sites open by the end of September 2023; 18 sites are currently active with four more expected by the end of August.

Crude 28-day mortality results, thus far, continue to exceed efficacy targets. While the Company continues to witness the benefits of its enrollment initiatives, Management believes that the Company will realize increasing benefit from these and other initiatives over time. Management looks forward to reporting additional Tigris progress and milestones as material developments unfold.